Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 28, 2015 11:12 PM ET

Biotechnology

Company Overview of Kindred Biosciences, Inc.

Company Overview

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidate is SentiKin, an oral analgesic formulation of flupirtine to manage post-operative pain in dogs, cats, and horses. The company's other small molecule product candidates consist of KIND-010 for management of weight loss in cats; and KIND-012 for treatment of fevers in horses. It is also developing biologics products, such as KIND-510, a feline erythropoeitin for treatment of anemia in cats; KIND-502 for the treatment of ...

1555 Bayshore Highway

Suite 200

Burlingame, CA 94010

United States

Founded in 2012

43 Employees

Phone:

650-701-7901

Key Executives for Kindred Biosciences, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 48
Total Annual Compensation: $495.5K
Co-Founder, Chief Operating Officer and Secretary
Age: 48
Total Annual Compensation: $386.9K
Chief Scientific Officer and Executive Vice President of Regulatory Affairs & Quality
Age: 64
Total Annual Compensation: $345.7K
Compensation as of Fiscal Year 2014.

Kindred Biosciences, Inc. Key Developments

Kindred Biosciences, Inc. Announces Unaudited Financial Results for the Second Quarter and Six Months Ended June 30, 2015

Kindred Biosciences, Inc. announced unaudited financial results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported a net loss of $6.9 million or $0.35 per diluted share, as compared to a net loss of $8.1 million or $0.42 per diluted share for the same period in 2014. Loss from operations was $6.912 million against $8.143 million a year ago. For the six months, net loss was $13.6 million or $0.69 per diluted share, as compared to a net loss of $14.3 million or $0.80 per diluted share for the same period in 2014. Loss from operations was $13.674 million against $14.320 million a year ago. Net cash used in operating activities for the six months ended June 30, 2015 was approximately $11.4 million.

Kindred Biosciences, Inc.(NasdaqCM:KIN) dropped from Russell 2000 Index

Kindred Biosciences, Inc. will be removed from Russell 2000 Index

Kindred Biosciences, Inc.(NasdaqCM:KIN) dropped from Russell 3000 Index

Kindred Biosciences, Inc. will be removed from the Russell 3000 Index.

Similar Private Companies By Industry

Company Name Region
Algal Scientific Corporation United States
Edwards Lifesciences Cardiovascular Resources Inc. United States
InterMune, Inc. United States
NaniRx Therapeutics, Inc. United States
Innomed Healthscience, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Kindred Biosciences, Inc., please visit www.kindredbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.